BRIEF—Shionogi inks EU distribution deal for Rizmoic

Japan’s Shionogi has agreed terms with Italy-based Molteni Farmaceutici for the distribution and sale of Rizmoic (naldemedine) in Italy and Poland. Shionogi will help promote the therapy.

Rizmoic was recently approved in Europe for the treatment of opioid-induced constipation (OIC) in adults previously treated with a laxative.

Molteni managing director Giuseppe Seghi Recli was optimistic about “raising a new patient’s awareness” of the products value in tackling “this disabling and under diagnosed pathology.”

Shionogi plans a European pediatric study in this indication, as well as a study in adults with post-operative ileus.